<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878666</url>
  </required_header>
  <id_info>
    <org_study_id>UKT HT03_1</org_study_id>
    <nct_id>NCT04878666</nct_id>
  </id_info>
  <brief_title>Prospective Assessment of Quality of Life in Patients With Locally Recurrent Breast Cancer and Hyperthermic Radiotherapy</brief_title>
  <acronym>UKT HT03_1</acronym>
  <official_title>Prospektive Erfassung Der Lebensqualität Bei Patientinnen Mit Lokal Rezidiviertem Mammakarzinom Und Hyperthermer Radiotherapie (UKT HT03.1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective assessment of Quality of Life in patients with locally recurrent breast cancer&#xD;
      after close R0, R1 or R2 resection or local inoperability and hyperthermic radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective monocentric trial evaluates the health-related Quality of Life in patients&#xD;
      with local recurrence of Breast cancer after close R0, R1 or R2 resection or local&#xD;
      inoperability during and after radiotherapy in combination with hyperthermia of the chest&#xD;
      wall. The Health-related Quality of Life and the intensity of fatigue will be documented by&#xD;
      the EORTC QLQ-C30, EORTC QLQ - BR 23, FACT - B + 4 and FACIT - Fatigue Questionnaires at the&#xD;
      end of the hypertermic radiotherapy and during follow-up after 3 and 12 month and then&#xD;
      annually up to year 5.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Evaluation of the health-related Quality of Life (QoL) during and after hyperthermic radiotherapy. QoL will be measured by the EORTC QLQ BR 23</measure>
    <time_frame>During hyperthermic radiotherapy up to five years of follow-up.</time_frame>
    <description>Assessment of the health-related QoL in patients who receive a surface hyperthermia in parallel with a radiotherapy of the chest wall as part of a multimodal therapy. This endpoint will be evaluated by the -BR 23 subscale (4 functional subscales, 4 symptom subscales.All subscales have a point value range from 0 to 100 points. A higher score represents better function and a higher quality of life. With symptom subscales, however, a higher score represents a higher level of symptoms or problems.</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a histologically confirmed local recurrence of breast cancer after close R0,&#xD;
        R1 or R2 resection respectively inoperable recurrence of the chest wall with or without a&#xD;
        previous irradiation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed local recurrence of breast cancer after close resection (≤1mm&#xD;
             Resection margin), R1 or R2 resection respectively inoperable recurrence of the chest&#xD;
             wall&#xD;
&#xD;
          -  age ≥18 Jahre&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Estimated life expectancy more than 2 years&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extensive distant metastases that have an estimated life expectancy of &lt;2a&#xD;
&#xD;
          -  Heart disease: severe heart failure (NHYA III / IV), coronary heart disease, state&#xD;
             after Myocardial infarction within the last 6 months), AV block III °&#xD;
&#xD;
          -  Cardiac pacemaker&#xD;
&#xD;
          -  Second malignancy (except cervical carcinomas in situ, local controlled basaliomas,&#xD;
             superficial bladder carcinomas (Ta, Tis, T1) or other carcinomas that have lasted more&#xD;
             than 5 years behind and have been treated curatively)&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Implanted port on the side to be treated in the Hyperthermia field (located&#xD;
             contralateral is not an exclusion criteria)&#xD;
&#xD;
          -  Subclavian vein thrombosis less than &lt;6 months behind&#xD;
&#xD;
          -  Other circumstances that preclude hyperthermia&#xD;
&#xD;
          -  Circumstances that conflict with regular follow-up care&#xD;
&#xD;
          -  Transplanted organs&#xD;
&#xD;
          -  Other implants of the ipsilateral chest wall&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Heinrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Heinrich, MD</last_name>
    <phone>+49 (0) 7071 29-</phone>
    <phone_ext>82165</phone_ext>
    <email>vanessa.heinrich@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Zips, MD, Prof.</last_name>
    <phone>+49 (0) 7071 29-</phone>
    <phone_ext>82165</phone_ext>
    <email>ro-info@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tübingen, Department of Radiation Oncology</name>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Heinrich, MD</last_name>
      <phone>+49 (0)7071 29-</phone>
      <phone_ext>82165</phone_ext>
      <email>Vanessa.heinrich@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Zips, MD, Prof.</last_name>
      <phone>+49 (0)7071 29-</phone>
      <phone_ext>82165</phone_ext>
      <email>ro-info@med.uni-tuebingen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperthermic Radiotherapy</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>locally recurrent Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

